肝細胞癌の発癌・進展の分子機構：造影超音波クッパー相と遺伝子発現を用いた融合解析

2012 年度 実績報告書

• 研究課題/領域番号: 23650312
• 研究機関: 近畿大学
• 研究代表者: 工藤 正俊 近畿大学, 医学部, 教授 (10298953)
• 研究分担者: 井上 達夫 近畿大学, 医学部, 講師 (20441024)
• キーワード: 超音波医科学 / ソナゾイド造影超音波 / 肝細胞癌 / クッパー細胞 / 遺伝子多型

研究概要

EOB-MRIの肝細胞相や、ソナゾイド造影超音波のクッパー相で低信号を呈する結節の生検組織をBmi-1、HSP70、Glutamine Synthetase、Glypican3などで染色した。この結果、EOB-MRIの肝細胞相で低信号を呈する乏血性結節は、70%以上の症例においてHSP70、Glypican3、Glutamine Synthetase、Bmi-1の発現がみられ、すでに早期肝細胞癌と呼べる所見であることが判明した。また、ソナゾイド造影超音波のクッパー相において低エコーを示す結節においてはHSP70、Glypican3、Glutamine Synthetase、Bmi-1のいずれかがほぼ100%発現しており、乏血性結節であっても、ソナゾイド造影超音波で低エコーを示す結節においてはクッパー機能の低下がみられ、すでに早期肝細胞癌と呼ばれる所見であることが判明した。したがって、EOB-MRIの肝細胞相で低信号を示す乏血性結節の7～8割ならびにソナゾイド造影超音波のクッパー相で低エコーを示す結節のほぼすべては将来的に多血性の古典的肝癌へ進展する可能性のある結節である。また、EOBの取り込み型トランスポーターであるOATB1B3を染色したところOATB1B3はEOB-MRI肝細胞相で低信号を示す結節の全例において発現低下を認めた。このようなことから、発がん初期にはOATB1B3の発現が低下し、少し遅れてクッパー細胞が低下し、動脈血流の増加へとつながっていくことが示唆された。したがって、乏血性結節であってもCD68染色で染色されるクッパー細胞相で低エコーを示す乏血性結節は臨床的に治療対象結節であると結論することができる。

研究成果

• [雑誌論文] Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases. (2012)
  • 著者名/発表者名: Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, Kudo M
  • 雑誌名: J Med Ultrason 巻: 28 ページ: 15-19
  • 査読あり
• [雑誌論文] Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. (2012)
  • 著者名/発表者名: Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M
  • 雑誌名: J Hepatol 巻: 56 ページ: 886-892
  • 査読あり
• [雑誌論文] Well-differentiated hepatocellular carcinoma detected as hypovascularity by only CT during hepatic arteriography. (2012)
  • 著者名/発表者名: Saito J, Kim SR, Kuod M, Imoto S, Ando K, Nakajima T, Fukuda K, Otono Y, Kim SK, Komaki T, Yano H, Nakashima O, Sugimoto K, Matsuoka T
  • 雑誌名: Intern Med 巻: 51 ページ: 885-890
  • 査読あり
• [雑誌論文] First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. (2012)
  • 著者名/発表者名: Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA
  • 雑誌名: Int J Clin Pract 巻: 66 ページ: 675-683
  • 査読あり
• [雑誌論文] Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function ? (2012)
  • 著者名/発表者名: Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, Kudo M, Murakami T
  • 雑誌名: Hepatob Pancreatic Dis Int 巻: 11 ページ: 307-313
  • 査読あり
• [雑誌論文] Activation of JNK and high expression level of CD133 predict a poor response to Sorafenib in hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T
  • 雑誌名: Brit J Cancer 巻: 106 ページ: 1997-2003
  • 査読あり
• [雑誌論文] Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers. (2012)
  • 著者名/発表者名: agiwara S, Sakurai T, Nishina S, Tanaka K, Ikeda M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Nagai T, Hayaishi S, Arizumi T, Park AM, Munakata H, Nishida N, Kudo M
  • 雑誌名: Digest Dis 巻: 30 ページ: 541-546
  • 査読あり
• [雑誌論文] Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection. (2012)
  • 著者名/発表者名: ishida N, Arizumi T, Hayaishi S, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ikai I, Kudo M
  • 雑誌名: Digest Dis 巻: 30 ページ: 547-553
  • 査読あり
• [雑誌論文] Retreatment with peginterferon alfa-2a plus ribavirin in patients who failed previous peginterferon alfa-2b plus ribavirin combination therapy. (2012)
  • 著者名/発表者名: Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Inao M, Tanaka A, Kaito M, Imazaki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, Kudo M, for RETRY study group:
  • 雑誌名: Digest Dis 巻: 30 ページ: 554-560
  • 査読あり
• [雑誌論文] Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. (2012)
  • 著者名/発表者名: Minami Y, Kudo M
  • 雑誌名: Digest Dis 巻: 30 ページ: 592-597
  • 査読あり
• [雑誌論文] Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a aingle center experience. (2012)
  • 著者名/発表者名: Kudo M, Ueshima K, Arizumi T
  • 雑誌名: Digest Dis 巻: 30 ページ: 609-616
  • 査読あり
• [雑誌論文] Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. (2012)
  • 著者名/発表者名: Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, Kudo M, Murakami T
  • 雑誌名: Eur J Radiol 巻: 81 ページ: 1460-1464
  • 査読あり
• [雑誌論文] Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A
  • 雑誌名: Hepatology 巻: 56 ページ: 994-1003
  • 査読あり
• [雑誌論文] Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Kudo M
  • 雑誌名: World J Gastroenterol 巻: 18 ページ: 6005-6017
  • 査読あり
• [雑誌論文] A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K
  • 雑誌名: Invest New Drug 巻: 30 ページ: 2015-2025
  • 査読あり
• [雑誌論文] Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Hagiwara S, Kudo M, Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T
  • 雑誌名: Hepatol Res 巻: 42 ページ: 394-400
  • 査読あり
• [雑誌論文] Targeted therapy for liver cancer: updated review in 2012. (2012)
  • 著者名/発表者名: Kudo M
  • 雑誌名: Curr Cancer Drug Tar 巻: 12 ページ: 1062-1072
  • 査読あり
• [雑誌論文] Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. (2012)
  • 著者名/発表者名: Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y
  • 雑誌名: Hepatol Res 巻: 42 ページ: 523-542
  • 査読あり
• [雑誌論文] Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. (2012)
  • 著者名/発表者名: Clavien PA
  • 雑誌名: Lancet Oncol 巻: 13 ページ: e11-22
  • 査読あり
• [雑誌論文] Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation. (2012)
  • 著者名/発表者名: Minami Y
  • 雑誌名: Eur J Radiol 巻: 81 ページ: e277-280
  • 査読あり
• [雑誌論文] Current status of hepatocellular carcinoma treatment in Japan: Case study and discussion-voting system. (2012)
  • 著者名/発表者名: Kudo M
  • 雑誌名: Clin Drug Invest 巻: 32 ページ: suppl.2:37-51
  • 査読あり
• [雑誌論文] Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging. (2012)
  • 著者名/発表者名: Shiina T
  • 雑誌名: Jpn J Appl Phys 巻: 51 ページ: 07GF11-1-8
  • 査読あり
• [雑誌論文] Risk of HCC development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα2a. (2012)
  • 著者名/発表者名: Hagiwara S
  • 雑誌名: Digest Dis 巻: 30 ページ: 561-567
  • 査読あり
• [雑誌論文] Histopathological diagnosis of early HCC through biopsy -efficacy of victoria blue and cytokeratin 7 staining-. (2012)
  • 著者名/発表者名: Kobayashi S
  • 雑誌名: Digest Dis 巻: 30 ページ: 574-579
  • 査読あり
• [雑誌論文] Novel non-trocar technique for laparoscopic radiofrequency ablation. (2012)
  • 著者名/発表者名: Tsuchida S
  • 雑誌名: Digest Dis 巻: 30 ページ: 588-591
  • 査読あり
• [雑誌論文] Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. (2012)
  • 著者名/発表者名: Kudo M
  • 雑誌名: Liver Cancer 巻: 1(3) ページ: 141-143
  • 査読あり
• [雑誌論文] Assessment of Gd-EOB-DTPA–enhanced MRI for HCC and Dysplastic nodule and comparison of detection sensitivity versus MDCT. (2012)
  • 著者名/発表者名: Inoue T
  • 雑誌名: J Gastroenterol 巻: 47 ページ: 1036-1047
  • 査読あり
• [学会発表] The retrospective study of novel anticancer agent, miriplatin in TACE and TAI for unresectable hepatocellular carcinoma in Japan. (2012)
  • 著者名/発表者名: Nagai N
  • 学会等名: Asian Pacific Digestive Week (APDW) 2012
  • 発表場所: Bangkok, Thailand
  • 年月日: 20121205-20121208
• [学会発表] Feasibility study of iron density quantification in liver with single source dual energy CT with first kVp switching. (2012)
  • 著者名/発表者名: Sasaki K
  • 学会等名: 98th Scientific Assembly and Annual Meeting (RSNA 2012)
  • 発表場所: Chicago, USA
  • 年月日: 20121125-20121130
• [学会発表] Role of hepatic resection for hepatocellular carcinoma: analysis of the HCC BRIDGE study. (2012)
  • 著者名/発表者名: Roayaie S
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston
  • 年月日: 20121109-20121113
• [学会発表] Efficacy and safety of miriplatin for hepatocellular carcinoma: a multi-center retrospective study in Japan. (2012)
  • 著者名/発表者名: Arai K
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston, USA
  • 年月日: 20121109-20121113
• [学会発表] Sorafenib deteriorates liver function in patients with advanced hepatocellular carcinoma: a multi-center retrospective study in Japan. (2012)
  • 著者名/発表者名: Sunagozaka H
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston, USA
  • 年月日: 20121109-20121113
• [学会発表] Predicting the treatment efficacy of sorafenib in patients for hepatocellular carcinoma: a multi-center retrospective study in Japan. (2012)
  • 著者名/発表者名: Yamashita T
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston, USA
  • 年月日: 20121109-20121113
• [学会発表] Surgical resection for lymph node metastasis from hepatocellular carcinoma: a report of the Japanese nationwide survey. (2012)
  • 著者名/発表者名: Hasegawa K
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston, USA
  • 年月日: 20121109-20121113
• [学会発表] Observations of hepatocellular carcinoma(HCC) management patterns from the global HCC BRIDGE study: global comparison of outcomes by locoregional therapy. (2012)
  • 著者名/発表者名: Schwartz M
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston, USA
  • 年月日: 20121109-20121113
• [学会発表] GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with SoraeNib) second interim analysis: subgoup analysis by disease aetiology. (2012)
  • 著者名/発表者名: Bronowicki JP
  • 学会等名: The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • 発表場所: Boston, USA
  • 年月日: 20121109-20121113
• [学会発表] “HCC challenges: Definition on TACE failure and refractoriness.” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management-
  • 発表場所: Taipei, Taiwan
  • 年月日: 20121103-20121103
  • 招待講演
• [学会発表] Final results of a randomized Phase II study of TSU-68 after transarterial chemoembolisation in Japanese patients with unresectable hepatocellular carcinoma. Chemoembolization. (2012)
  • 著者名/発表者名: Kaneko S
  • 学会等名: ESMO 2012
  • 発表場所: Vienna, Austria
  • 年月日: 20120928-20121002
• [学会発表] GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with soraeNib) second interim analysis: subgoup analysis by disease aetiology. (2012)
  • 著者名/発表者名: Bronowicki JP
  • 学会等名: ESMO 2012
  • 発表場所: Vienna, Austria
  • 年月日: 20120928-20121002
• [学会発表] Phase I/II trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC). (2012)
  • 著者名/発表者名: Ikeda K
  • 学会等名: ESMO 2012
  • 発表場所: Vienna, Austria
  • 年月日: 20120928-20121002
• [学会発表] Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase III Brisk-Ps Study. (2012)
  • 著者名/発表者名: Llovet JM
  • 学会等名: Sixth Annual Conference International Liver Cancer Association(ILCA)
  • 発表場所: Berlin, Germany
  • 年月日: 20120914-20120916
• [学会発表] The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Arizumi T
  • 学会等名: Sixth Annual Conference International Liver Cancer Association(ILCA)
  • 発表場所: Berlin, Germany
  • 年月日: 20120914-20120916
• [学会発表] Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: assessment of baseline and on-treatment alpha-fetoprotein levels in the phase III Brisk-Ps study. (2012)
  • 著者名/発表者名: Raoul JL
  • 学会等名: Sixth Annual Conference International Liver Cancer Association(ILCA)
  • 発表場所: Berlin, Germany
  • 年月日: 20120914-20120916
• [学会発表] Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: global comprison of outcomes by staging system. (2012)
  • 著者名/発表者名: Sherman M
  • 学会等名: Sixth Annual Conference International Liver Cancer Association(ILCA)
  • 発表場所: Berlin
  • 年月日: 20120914-20120916
• [学会発表] “Liver biopsy: Is it useful for staging?” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: Sixth Annual Conference International Liver Cancer Association(ILCA)
  • 発表場所: Berlin, Germany
  • 年月日: 20120914-20120916
  • 招待講演
• [学会発表] Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE Study: An interim analysis of HCC burden of illness in the Asia-Pacific (AP) cohort. (2012)
  • 著者名/発表者名: Orsini LS
  • 学会等名: International Society for Pharmacoeconomics and Outsomes Research (ISPOR) 5th Asia-Pacific Conference
  • 発表場所: Taipei, Taiwan
  • 年月日: 20120902-20120904
• [学会発表] “Real life experience with Nexavar: GIDEON 2nd IA” “Advanced HCC: rich evidence for Nexavar” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: Advances in HCC management in Asia
  • 発表場所: Ho Chi Minh , Vietnam
  • 年月日: 20120804-20120805
  • 招待講演
• [学会発表] “Controversies on the role of TACE” “Intermediate HCC” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: Advances in HCC management in Asia
  • 発表場所: Ho Chi Minh , Vietnam
  • 年月日: 20120804-20120805
  • 招待講演
• [学会発表] “Diagnosis by Imaging: Eastern approach” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: Program for the Advancement of Therapy in Hepatocellular Carcinoma (PATH)
  • 発表場所: Shanghai, China
  • 年月日: 20120709-20120710
  • 招待講演
• [学会発表] “Management of TACE failure: Difinition on TACE failure/refractoriness” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC)
  • 発表場所: Shanghai, China
  • 年月日: 20120708-20120708
  • 招待講演
• [学会発表] “Review of the evidence suppporting combination therapy in intermediate HCC: GIDEON” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC)
  • 発表場所: Shanghai, China
  • 年月日: 20120708-20120708
  • 招待講演
• [学会発表] “Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: an analysis of the Asian cohort. ” "Recent observation in the management of HCC" (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • 発表場所: Shanghai, China
  • 年月日: 20120706-20120708
  • 招待講演
• [学会発表] “Japanese treatment algorithm.“ Session XII ”Algorithm Consensus Discussion” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)
  • 発表場所: Shanghai, China
  • 年月日: 20120706-20120708
  • 招待講演
• [学会発表] Phase 1b dose-escalation study of a phase 2 randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC). (2012)
  • 著者名/発表者名: Cheng AL
  • 学会等名: ASCO 2012 Annual Meeting
  • 発表場所: Chicago,USA
  • 年月日: 20120601-20120605
• [学会発表] Observations of hepatocellular carcinoma (HCC) management patterns from the Global HCC BRIDGE Study: First characterization of the full study population. (2012)
  • 著者名/発表者名: Park JW
  • 学会等名: ASCO 2012 Annual Meeting
  • 発表場所: Chicago,USA
  • 年月日: 20120601-20120605
• [学会発表] Novel association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Nishida N
  • 学会等名: Digestive Disease Week(DDW) 2012
  • 発表場所: San Diego,USA
  • 年月日: 20120519-20120522
• [学会発表] Activation of JNK in the Non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Sakurai T
  • 学会等名: Digestive Disease Week(DDW) 2012
  • 発表場所: San Diego,USA
  • 年月日: 20120519-20120522
• [学会発表] The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma. (2012)
  • 著者名/発表者名: Arizumi T
  • 学会等名: Digestive Disease Week(DDW) 2012
  • 発表場所: San Diego,USA
  • 年月日: 20120519-20120522
• [学会発表] The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced sonography using perfluorocarbon microbubbles (sonazoid). (2012)
  • 著者名/発表者名: Minami Y
  • 学会等名: Digestive Disease Week(DDW) 2012
  • 発表場所: San Diego,USA
  • 年月日: 20120519-20120522
• [学会発表] Usefulness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: comparison with contrast-enhanced CT. (2012)
  • 著者名/発表者名: Inoue T
  • 学会等名: Digestive Disease Week(DDW) 2012
  • 発表場所: San Diego,USA
  • 年月日: 20120519-20120522
• [学会発表] “CEUS as a screening tool of HCC in cirrhotic liver. ” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging
  • 発表場所: Korea
  • 年月日: 20120511-20120513
  • 招待講演
• [学会発表] “CEUS in the pancreatobiliary intervention. ” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging
  • 発表場所: Korea
  • 年月日: 20120511-20120513
  • 招待講演
• [学会発表] “Endoscopic ultrasound in the differential diagnosis of cystic pancreatic lesions: do we always need it? ” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: EFSUMB Annual Meeting EUROSON 2012
  • 発表場所: Madrid, Spain
  • 年月日: 20120422-20120422
  • 招待講演
• [学会発表] Clinical findings in Child-pugh B score subgourps. (2012)
  • 著者名/発表者名: Bronowicki JP
  • 学会等名: 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • 発表場所: Barcelona,Spain
  • 年月日: 20120418-20120422
• [学会発表] Observed patterns of systemic therapy use in hepatocellular carcinoma (HCC) patients from the multinational HCC BRIDGE Study: Results of a second interim analysis. (2012)
  • 著者名/発表者名: Colombo M
  • 学会等名: 47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)
  • 発表場所: Barcelona,Spain
  • 年月日: 20120418-20120422
• [学会発表] “The role of TACE & Nexavar in HCC treatment.” (2012)
  • 著者名/発表者名: Kudo M
  • 学会等名: HCC Expert Symposium on Tumor Therapy
  • 発表場所: Seoul, Korea
  • 年月日: 20120407-20120408
  • 招待講演